Incidence of SARS-CoV-2 infection according to baseline antibody status in staff and residents of 100 long-term care facilities (VIVALDI): a prospective cohort study

  1. Maria Krutikov
  2. Tom Palmer
  3. Gokhan Tut
  4. Chris Fuller
  5. Madhumita Shrotri
  6. Haydn Williams
  7. Daniel Davies
  8. Aidan Irwin-Singer
  9. James Robson
  10. Andrew Hayward
  11. Paul Moss
  12. Andrew Copas
  13. Laura Shallcross

Reviewed by

Read the full article

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1016/s2666-7568(21)00093-3
  2. ScreenIT

    SciScore for 10.1101/2021.03.08.21253110: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board StatementConsent: Eligible LTCFs were identified by the FSHC and written informed consent to participate was sought from all participants.
    IRB: Ethics: Ethical approval for this study was obtained from the South Central - Hampshire B Research Ethics Committee, REC Ref: 20/SC/0238.
    RandomizationFor comparison, control samples were retrieved for 23 residents and 19 staff from five randomly selected care homes who met the following criteria: antibodies to nucleocapsid (Abbott) detected at the first blood testing round; three antibody tests; no record of PCR positive test; at least one PCR test result during the analysis period.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    Quantitative IgG antibody titres were measured against spike (S) protein and nucleocapsid protein (N) using the MSD V-PLEX COVID-19 Respiratory Panel 2 (96-well, 10 Spot Plate was coated with three SARS CoV-2 antigens (S, S-RBD S-NTD and N)) (Cat # K15372U) from Meso Scale Diagnostics, Rockville, MD USA (Appendix).
    nucleocapsid protein (N) using the MSD V-PLEX COVID-19 Respiratory Panel 2 (96-well, 10 Spot Plate was coated with three SARS CoV-2 antigens (S, S-RBD S-NTD and N)) (Cat # K15372U) from Meso Scale Diagnostics, Rockville, MD USA (Appendix)
    suggested: None
    N
    suggested: None
    Software and Algorithms
    SentencesResources
    Laboratory methods: Blood samples were tested for IgG to nucleocapsid (N) protein using the Abbott ARCHITECT i system (Abbott, Maidenhead, UK), a semi-quantitative chemiluminescent microparticle immunoassay.
    Abbott
    suggested: (Abbott, RRID:SCR_010477)
    12 All analysis was conducted in STATA v16.0.
    STATA
    suggested: (Stata, RRID:SCR_012763)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    To overcome this limitation, we reduced the test index threshold for the Abbott assay to 0.8, which has been shown to increase sensitivity with minimal effect on test specificity. As vaccination coverage in residents approaches 100%, 29 it will be important to understand whether vaccination and natural infection provide comparable levels of protection against new infection. New infections were still evident in our dataset in February 2021, and work is ongoing to investigate the effectiveness of different vaccine types and dosing schedules in this population. However, the high degree of vaccine coverage in residents will make it challenging to investigate protective effectiveness in this group. In summary, the risk of a second SARS-CoV-2 infection is substantially reduced in staff and residents of LTCFs who are SARS-CoV-2 seropositive and the observed reinfections were not clinically severe. Understanding the correlates of immunity that protect against future infection will be fundamental to policy decisions regarding LTCFs, including re-vaccination schedules and the ongoing need for NPIs to prevent SARS-CoV-2 transmission.

    Results from TrialIdentifier: We found the following clinical trial numbers in your paper:

    IdentifierStatusTitle
    ISRCTN14447421NANA

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2021.03.08.21253110v1 on medRxiv